Engineering a multi-epitope vaccine candidate against Leishmania infantum using comprehensive Immunoinformatics methods

Shams, Morteza; Nourmohammadi, Hassan; Majidiani, Hamidreza; Shariatzadeh, Seyyed Ali; Asghari, Ali; Fatollahzadeh, Mohammad; Irannejad, Hamid

doi:10.1007/s11756-021-00934-3

Cited by 5 publications

(6 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From the immunoinformatic approaches used in this study for SARS-CoV-2 in the design of multi-epitope vaccines against other pathogens such as MERS-CoV 47 , Nipah virus 72 , Zika 73 , dengue 74 , Hendra virus 75 , Malaria 76 , Acinetobacter baumannii 77 , Leishmania infantum 78 , Pseudomonas aeruginosa 79 , Klebsiella pneumoniae 80 , Kaposi sarcoma 81 and several other examples have also been used. A similar strategy has also been used to make a vaccine against cancer antigens.…”

Section: Discussionmentioning

confidence: 99%

Immunoinformatics design of a structural proteins driven multi-epitope candidate vaccine against different SARS-CoV-2 variants based on fynomer

Sarvmeili,

Baghban Kohnehrouz,

Gholizadeh

et al. 2024

Sci Rep

View full text Add to dashboard Cite

The ideal vaccines for combating diseases that may emerge in the future require more than simply inactivating a few pathogenic strains. This study aims to provide a peptide-based multi-epitope vaccine effective against various severe acute respiratory syndrome coronavirus 2 strains. To design the vaccine, a library of peptides from the spike, nucleocapsid, membrane, and envelope structural proteins of various strains was prepared. Then, the final vaccine structure was optimized using the fully protected epitopes and the fynomer scaffold. Using bioinformatics tools, the antigenicity, allergenicity, toxicity, physicochemical properties, population coverage, and secondary and three-dimensional structures of the vaccine candidate were evaluated. The bioinformatic analyses confirmed the high quality of the vaccine. According to further investigations, this structure is similar to native protein and there is a stable and strong interaction between vaccine and receptors. Based on molecular dynamics simulation, structural compactness and stability in binding were also observed. In addition, the immune simulation showed that the vaccine can stimulate immune responses similar to real conditions. Finally, codon optimization and in silico cloning confirmed efficient expression in Escherichia coli. In conclusion, the fynomer-based vaccine can be considered as a new style in designing and updating vaccines to protect against coronavirus disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Immunoinformatics design of a structural proteins driven multi-epitope candidate vaccine against different SARS-CoV-2 variants based on fynomer

Sarvmeili,

Baghban Kohnehrouz,

Gholizadeh

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…An efficacious vaccine candidate against leishmaniasis is anticipated to elicit functional and protective immune responses by igniting the leishmanicidal properties of macrophages, hence preventing the increase in parasite load and subsequent pathological immune imbalance [ 45 ]. So far, different vaccination strategies have been used to design vaccines that prevent human and/or canine leishmaniasis [ 5 ]. Subunit vaccines are of particular interest among others since they carry immunogenic components of a given pathogenic organism.…”

Section: Discussionmentioning

confidence: 99%

“…In many areas, CL is recognized as the most widespread type of the infection, with a particular impact on 0.7-1.2 million individuals, mostly in the Americas, Central Asia, the Middle East, and the Mediterranean Basin [ 4 ], whereas VL (so-called as kala-azar) is the most severe form with an incidence rate of 50,000 to 90,000 individuals annually, particularly in Brazil, eastern Africa, and the Indian subcontinent. Leishmania donovani ( L. donovani ) and L. infantum are known as the principal agents of VL [ 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

In Silico Characterization of an Important Metacyclogenesis Marker in Leishmania donovani, HASPB1, as a Potential Vaccine Candidate

Kordi,

Basmenj,

Majidiani

et al. 2023

BioMed Research International

Self Cite

View full text Add to dashboard Cite

Visceral leishmaniasis is a life-threatening infectious disease worldwide. Extensive experiments have been done to introduce potential vaccine candidates to combat leishmaniasis. The present study was done to evaluate Leishmania donovani hydrophilic acylated surface protein B1 as a potential vaccine candidate using in silico methods. For this aim, server-based predictions were performed regarding physicochemical characteristics, solubility, antigenicity, allergenicity, signal peptide, transmembrane domain, and posttranslational modifications (PTMs). Also, secondary and tertiary structures were predicted using NetSurfP-3.0 and I-TASSER, respectively. The 3D model was further subjected to refinement and validation, and promising B-cell, cytotoxic T-lymphocyte (CTL; human, dog), and helper T-lymphocyte (HTL; human) epitopes were predicted. The protein had a molecular weight of 42.19 kDa, with high solubility (0.749), stability (instability index: 21.34), and hydrophilicity (GRAVY: -2.322). No signal peptide or transmembrane domain was predicted, and the most abundant PTMs were phosphorylation, O-glycosylation, and acetylation. Many coils and disordered regions existed in the secondary structure analysis, and the tertiary model had a good confidence score (-0.79). Next, the ProSA-web and PROCHECK tools showed adequate improvements in the refined model compared to the crude model. Only 4 shared B-cell epitopes among three web servers (ABCpred, BepiPred 2.0, and SVMTriP) were shown to be antigenic, nonallergenic, and with good water solubility. Also, five potent CTL epitopes in dogs and five in humans were predicted. Notably, two HTL epitopes were found to be potential IFN-γ inducers. In conclusion, our results demonstrated several immunogenic epitopes in this protein, which could be directed towards multiepitope vaccine design.

show abstract

“…Firstly, we used VaxiJen to analyze the antigenicity of individual epitopes and screen out epitopes with a threshold above 0.4. In addition, epitopes with high antigenicity were analyzed by AllergenFP ( http://www.ddg-pharmfac.net/AllergenFP/ ), and non-allergenic epitopes were screened out [ 36 ]. Therefore, the epitopes with antigenicity greater than 0.4 and non-allergenic were selected to construct MEVs.…”

Section: Methodsmentioning

confidence: 99%

Designing a conjugate vaccine targeting Klebsiella pneumoniae ST258 and ST11

Li,

Yu,

Yuan

et al. 2024

Heliyon

View full text Add to dashboard Cite

Engineering a multi-epitope vaccine candidate against Leishmania infantum using comprehensive Immunoinformatics methods

Cited by 5 publications

References 68 publications

Immunoinformatics design of a structural proteins driven multi-epitope candidate vaccine against different SARS-CoV-2 variants based on fynomer

Immunoinformatics design of a structural proteins driven multi-epitope candidate vaccine against different SARS-CoV-2 variants based on fynomer

In Silico Characterization of an Important Metacyclogenesis Marker in Leishmania donovani, HASPB1, as a Potential Vaccine Candidate

Designing a conjugate vaccine targeting Klebsiella pneumoniae ST258 and ST11

Contact Info

Product

Resources

About